Search

Your search keyword '"Naso R"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Naso R" Remove constraint Author: "Naso R"
98 results on '"Naso R"'

Search Results

4. Phenotypic and Genotypic Characterization of Nosocomial Staphylococcus aureus Isolates from Trauma Patients

8. PI-46Pharmacokinetics (PK), safety, and pharmacodynamics (PD) of Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), in a phase 1 single dose, dose escalating study in normal healthy volunteers (NHVS).

12. A Noncovalent Complex Vaccine Prepared with Detoxified Escherichia coli J5 (Rc Chemotype) Lipopolysaccharide and Neisseria meningitidis Group B Outer Membrane Protein Produces Protective Antibodies against Gram-Negative Bacteremia

14. Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines

15. Potent Inhibition of NTPase/Helicase of the West Nile Virus by Ring-Expanded (“Fat”) Nucleoside Analogues

16. Ring-Expanded (“Fat”) Nucleoside and Nucleotide Analogues Exhibit Potent in Vitro Activity against Flaviviridae NTPases/Helicases, Including Those of the West Nile Virus, Hepatitis C Virus, and Japanese Encephalitis Virus

18. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.

19. Selective decrease in the rate of cleavage of an intracellular precursor to Rauscher leukemia virus p30 by treatment of infected cells with actinomycin D

20. Comparative analysis: intracellular precursor polyproteins of baboon endogenous retroviruses and human viral isolate HL23V

21. Phenotypic and Genotypic Characterization of Nosocomial Staphylococcus aureusIsolates from Trauma Patients

22. Further studies on the glycosylated gag gene products of Rauscher murine leukemia virus: identification of an N-terminal 45,000-dalton cleavage product

23. Polyprotein Precursors to Mouse Mammary Tumor Virus Proteins

24. Characterization of 40,000- and 25,000-dalton intermediate precursors to Rauscher murine leukemia virus gag gene products

25. Common Precursor for Rauscher Leukemia Virus gp69/71, p15(E), and p12(E)

26. Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection

27. Purification of Large Amounts of Murine Ribonucleic Acid Tumor Viruses Produced in Roller Bottle Cultures

29. PI-46.

32. Medien zur Anderswelt

33. Medien zur Anderswelt.: Waffenentäusserungen im Kontext von Gräbern, Horten und Ritualorten im Alpenrheintal

34. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

35. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.

36. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.

37. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome.

38. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.

39. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.

40. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.

41. Staphylococcus aureus vaccination for dialysis patients--an update.

42. Staphylococcal vaccines: a realistic dream.

43. Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections.

44. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.

45. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.

46. Cloning of the amino terminal nucleotides of the antigen I/II of Streptococcus sobrinus and the immune responses to the corresponding synthetic peptides.

47. Proteins of Rauscher murine leukemia virus: resolution of a 70,000-dalton, Nonglycosylated polypeptide containing p30 peptide sequences.

48. The cell-free translation of Rauscher leukemia virus RNA into high molecular weight polypeptides.

50. Further characterization of intracellular precursor polyproteins of Rauscher leukemia virus.

Catalog

Books, media, physical & digital resources